By studying individuals who spontaneously clear hepatitis C infections, a team of researchers has identified viable vaccine targets for a disease that infects 70 million worldwide with case numbers increasing every year...
In recent years, we’ve witnessed some truly inspiring progress in vaccine development. That includes the mRNA vaccines that were so critical during the COVID-19 pandemic, the first approved vaccine for respiratory...
A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced. The vaccine showed success in stimulating production of rare immune cells...
Scientists are engineering vaccines that turn cells into antibody factories The Conference on Retroviruses and Opportunistic Infections (CROI 2020) heard this week how scientists had, for the first time, devised a...
An experimental HIV vaccine developed by scientists at Scripps Research and the nonprofit vaccine research organization IAVI has reached an important milestone by eliciting antibodies that can neutralize a wide variety...
Early mutation in neutralizing antibody gives it flexibility to adapt to virus’s changes In the quest to develop an effective HIV vaccine, researchers have focused attention on identifying and targeting the region...
A series of new studies led by scientists at The Scripps Research Institute (TSRI) and the International AIDS Vaccine Initiative (IAVI) describe a potential vaccination strategy to jump-start the selection and evolution...
A discovery made by Duke researchers is shedding light on a potential new strategy for producing an effective HIV vaccine. The human body is capable under certain conditions of creating broadly neutralizing HIV-1...